

Xian-Jin Xie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5123277/publications.pdf>

Version: 2024-02-01

54
papers

3,132
citations

236925

25
h-index

155660

55
g-index

59
all docs

59
docs citations

59
times ranked

6372
citing authors

#	ARTICLE	IF	CITATIONS
1	Flexible, rule-based dose escalation: The cohort-sequence design. <i>Contemporary Clinical Trials Communications</i> , 2020, 17, 100541.	1.1	2
2	A Phase 2 Clinical Trial of SABR Followed by Immediate Vertebroplasty for Spine Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 83-89.	0.8	26
3	Comparison of Dako HercepTest and Ventana PATHWAY Anti-HER2 (4B5) Tests and Their Correlation With Fluorescent In Situ Hybridization in Breast Carcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 403-409.	1.2	10
4	NQO1-dependent, Tumor-selective Radiosensitization of Non-small Cell Lung Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 2601-2609.	7.0	37
5	Determining the Adequate Examined Lymph Node Count in Resected Ampullary Adenocarcinoma: A National Cohort Study. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 792-801.	1.7	3
6	Investigating the power of goodness-of-fit tests for multinomial logistic regression. <i>Communications in Statistics Part B: Simulation and Computation</i> , 2018, 47, 1039-1055.	1.2	9
7	Minimally Invasive Versus Open Pancreaticoduodenectomy. <i>Annals of Surgery</i> , 2018, 268, 151-157.	4.2	97
8	Adjuvant External Radiation Impacts Outcome of Pelvis-limited Stage III Endometrial Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 792-796.	1.3	8
9	Predicting severe hematologic toxicity from extended-field chemoradiation of para-aortic nodal metastases from cervical cancer. <i>Practical Radiation Oncology</i> , 2018, 8, 13-19.	2.1	12
10	Sustainability of Evidence-Based Acute Pain Management Practices for Hospitalized Older Adults. <i>Western Journal of Nursing Research</i> , 2018, 40, 1749-1764.	1.4	6
11	Value of combined adjuvant chemotherapy and radiation on survival for stage III uterine cancer: is less radiation equal to more?. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e49.	2.2	17
12	Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 91-100.	0.8	67
13	Modeling Renal Cell Carcinoma in Mice: <i>Bap1</i> and <i>Pbrm1</i> Inactivation Drive Tumor Grade. <i>Cancer Discovery</i> , 2017, 7, 900-917.	9.4	128
14	Time and Effort Required for Tissue Acquisition and Submission in Lung Cancer Clinical Trials. <i>Clinical Lung Cancer</i> , 2017, 18, 626-630.	2.6	7
15	Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer. <i>Journal of Surgical Oncology</i> , 2017, 116, 83-88.	1.7	24
16	Aspirin/antiplatelet agent use improves disease-free survival and reduces the risk of distant metastases in Stage II and III triple-negative breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 463-471.	2.5	33
17	A transistor-like pH nanoprobe for tumour detection and image-guided surgery. <i>Nature Biomedical Engineering</i> , 2017, 1, .	22.5	163
18	Nomogram to predict non-home discharge following pancreaticoduodenectomy in a national cohort of patients. <i>Hpb</i> , 2017, 19, 1037-1045.	0.3	11

#	ARTICLE	IF	CITATIONS
19	Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1489-1495.	1.1	46
20	Temporal trends for adjuvant radiation utilization and their effect on survival for locally advanced (stage III) endometrial cancer in the USA. <i>Journal of Radiation Oncology</i> , 2017, 6, 175-187.	0.7	4
21	PROTODADHERIN 7 Acts through SET and PP2A to Potentiate MAPK Signaling by EGFR and KRAS during Lung Tumorigenesis. <i>Cancer Research</i> , 2017, 77, 187-197.	0.9	55
22	Incorporating Oxygen-Enhanced MRI into Multi-Parametric Assessment of Human Prostate Cancer. <i>Diagnostics</i> , 2017, 7, 48.	2.6	23
23	SRC-2-mediated coactivation of anti-tumorigenic target genes suppresses MYC-induced liver cancer. <i>PLoS Genetics</i> , 2017, 13, e1006650.	3.5	16
24	Institutional Scientific Review of Cancer Clinical Research Protocols: A Unique Requirement That Affects Activation Timelines. <i>Journal of Oncology Practice</i> , 2017, 13, e982-e991.	2.5	5
25	SBRT for early-stage glottic larynx cancer—Initial clinical outcomes from a phase I clinical trial. <i>PLoS ONE</i> , 2017, 12, e0172055.	2.5	26
26	Stereotactic body radiation therapy for low and intermediate risk prostate cancer—Results from a multi-institutional clinical trial. <i>European Journal of Cancer</i> , 2016, 59, 142-151.	2.8	124
27	Targeting renal cell carcinoma with a HIF-2 antagonist. <i>Nature</i> , 2016, 539, 112-117.	27.8	521
28	Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma. <i>Molecular and Cellular Biology</i> , 2016, 36, 1836-1855.	2.3	33
29	Pretreatment biopsy analysis of DAB 2 IP identifies subpopulation of high-risk prostate cancer patients with worse survival following radiation therapy. <i>Cancer Medicine</i> , 2015, 4, 1844-1852.	2.8	7
30	Impact of NCI-Mandated Scientific Review on Protocol Development and Content. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 409-416.	4.9	5
31	Temporal Trends and Predictors for Cancer Clinical Trial Availability for Medically Underserved Populations. <i>Oncologist</i> , 2015, 20, 674-682.	3.7	21
32	Prediction of Cancer Prevention: From Mammogram Screening to Identification of BRCA1 / 2 Mutation Carriers in Underserved Populations. <i>EBioMedicine</i> , 2015, 2, 1827-1833.	6.1	10
33	Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma. <i>BMC Urology</i> , 2015, 15, 24.	1.4	11
34	Comprehensive functional characterization of cancer—testis antigens defines obligate participation in multiple hallmarks of cancer. <i>Nature Communications</i> , 2015, 6, 8840.	12.8	94
35	High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma. <i>Oncotarget</i> , 2015, 6, 16951-16962.	1.8	28
36	Differential Radiosensitivity Phenotypes of DNA-PKcs Mutations Affecting NHEJ and HRR Systems following Irradiation with Gamma-Rays or Very Low Fluences of Alpha Particles. <i>PLoS ONE</i> , 2014, 9, e93579.	2.5	13

#	ARTICLE	IF	CITATIONS
37	Aspirin improves outcome in high risk prostate cancer patients treated with radiation therapy. <i>Cancer Biology and Therapy</i> , 2014, 15, 699-706.	3.4	32
38	Orexin Regulates Bone Remodeling via a Dominant Positive Central Action and a Subordinate Negative Peripheral Action. <i>Cell Metabolism</i> , 2014, 19, 927-940.	16.2	38
39	<i>Bap1</i> is essential for kidney function and cooperates with <i>Vhl</i> in renal tumorigenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 16538-16543.	7.1	123
40	Evaluation of the Prognostic Significance of Altered Mammalian Target of Rapamycin Pathway Biomarkers in Upper Tract Urothelial Carcinoma. <i>Urology</i> , 2014, 84, 1134-1140.	1.0	18
41	Genome-wide si RNA screen reveals coupling between mitotic apoptosis and adaptation. <i>EMBO Journal</i> , 2014, 33, 1960-1976.	7.8	39
42	Predictors of Rectal Tolerance Observed in a Dose-Escalated Phase 1-2 Trial of Stereotactic Body Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 509-517.	0.8	177
43	DOC-2/DAB2 Interacting Protein Status in High-Risk Prostate Cancer Correlates With Outcome for Patients Treated With Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 729-735.	0.8	6
44	BAP1 Immunohistochemistry Predicts Outcomes in a Multi-Institutional Cohort with Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 191, 603-610.	0.4	69
45	Identification and Characterization of a Suite of Tumor Targeting Peptides for Non-Small Cell Lung Cancer. <i>Scientific Reports</i> , 2014, 4, 4480.	3.3	44
46	A Novel Germline Mutation in <i>BAP1</i> Predisposes to Familial Clear-Cell Renal Cell Carcinoma. <i>Molecular Cancer Research</i> , 2013, 11, 1061-1071.	3.4	135
47	Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. <i>Lancet Oncology</i> , The, 2013, 14, 159-167.	10.7	383
48	A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel. <i>RNA Biology</i> , 2013, 10, 1700-1713.	3.1	37
49	Pathologic complete response rates after neoadjuvant chemoradiation (CRT) for rectal cancer: Do novel agents have a role?. <i>Journal of Clinical Oncology</i> , 2012, 30, 597-597.	1.6	1
50	Pathological complete response rates after neoadjuvant chemoradiation (CRT) for rectal cancer: Do novel agents have a role?. <i>Journal of Clinical Oncology</i> , 2012, 30, e14165-e14165.	1.6	4
51	Brain metastases (BMs) from metastatic renal cell carcinoma (RCC) in patients (pts) treated with molecularly targeted agents (MTAs).. <i>Journal of Clinical Oncology</i> , 2012, 30, e15066-e15066.	1.6	0
52	Bayesian credible intervals for monitoring liquid blending rates. <i>Model Assisted Statistics and Applications</i> , 2011, 6, 75-80.	0.3	0
53	Statistical considerations for high throughput screening data. <i>Frontiers in Biology</i> , 2010, 5, 354-360.	0.7	0
54	Accounting for Intraclass Correlations and Controlling for Baseline Differences in a Cluster-Randomised Evidence-Based Practice Intervention Study. <i>Worldviews on Evidence-Based Nursing</i> , 2008, 5, 95-101.	2.9	3